Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
Ablynx (EBR:ABLX) GHENT, Belgium, 3 October 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, today announced that it has been awarded a grant worth €1.8 million by the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT).
Nanobodies® are a new class of therapeutic proteins comprising naturally-occurring single domain antibodies. The grant, which is over three years, allows Ablynx to further develop technologies related to its Nanobody® platform. Furthermore, this grant will enable Ablynx to expand its intellectual property portfolio.
"We are extremely pleased to receive another grant from IWT and for their continued support of Ablynx's Nanobody® technology platform. We believe this grant will allow us to dedicate a focused effort to look at novel technologies for our therapeutic Nanobodies® and add even further value to an already rapidly growing product portfolio", commented Dr Edwin Moses, Chief Executive Officer and Chairman of Ablynx. "This research will build on the extensive Nanobody® platform knowledge already possessed within Ablynx."
